Identification of a 5-gene Signature Panel for the Prediction of Prostate Cancer Progression

Overview

Journal Br J Cancer

Specialty Oncology

Date 2024 Oct 14

PMID 39402324

Authors

Michelle Shen

Fernando Garcia-Marques

Arvind Muruganantham

Shiqin Liu

James Robert White

Abel Bermudez

Meghan A Rice

Kelsey Thompson

Chun-Liang Chen

Chia-Nung Hung

Zhao Zhang

Tim H Huang

Michael A Liss

Kenneth J Pienta

Sharon J Pitteri

Tanya Stoyanova

Affiliations

Soon will be listed here.

Abstract

Background: Despite nearly 100% 5-year survival for localised prostate cancer, the survival rate for metastatic prostate cancer significantly declines to 32%. Thus, it is crucial to identify molecular indicators that reflect the progression from localised disease to metastatic prostate cancer.

Methods: To search for molecular indicators associated with prostate cancer metastasis, we performed proteomic analysis of rapid autopsy tissue samples from metastatic prostate cancer (N = 8) and localised prostate cancer (N = 2). Then, we utilised multiple independent, publicly available prostate cancer patient datasets to select candidates that also correlate with worse prostate cancer clinical prognosis.

Results: We identified 154 proteins with increased expressions in metastases relative to localised prostate cancer through proteomic analysis. From the subset of these candidates that correlate with prostate cancer recurrence (N = 28) and shorter disease-free survival (N = 37), we identified a 5-gene signature panel with improved performance in predicting worse clinical prognosis relative to individual candidates.

Conclusions: Our study presents a new 5-gene signature panel that is associated with worse clinical prognosis and is elevated in prostate cancer metastasis on both protein and mRNA levels. Our 5-gene signature panel represents a potential modality for the prediction of prostate cancer progression towards the onset of metastasis.

References

Waterhouse Jr R, Van Neste L, Moses K, Barnswell C, Silberstein J, Jalkut M . Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. Urology. 2018; 128:62-65. PMC: 10182891. DOI: 10.1016/j.urology.2018.04.001. View

Maji D, Glasser E, Henderson S, Galardi J, Pulvino M, Jenkins J . Representative cancer-associated U2AF2 mutations alter RNA interactions and splicing. J Biol Chem. 2020; 295(50):17148-17157. PMC: 7863893. DOI: 10.1074/jbc.RA120.015339. View

Drake J, Graham N, Lee J, Stoyanova T, Faltermeier C, Sud S . Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013; 110(49):E4762-9. PMC: 3856845. DOI: 10.1073/pnas.1319948110. View

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y . Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell. 2018; 34(6):996-1011.e8. PMC: 7444093. DOI: 10.1016/j.ccell.2018.10.016. View

Sun N, Zhao X . Therapeutic Implications of FABP4 in Cancer: An Emerging Target to Tackle Cancer. Front Pharmacol. 2022; 13:948610. PMC: 9310032. DOI: 10.3389/fphar.2022.948610. View

Fontana F, Anselmi M, Limonta P . Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy. Cancer Lett. 2022; 534:215619. DOI: 10.1016/j.canlet.2022.215619. View

Varambally S, Yu J, Laxman B, Rhodes D, Mehra R, Tomlins S . Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005; 8(5):393-406. DOI: 10.1016/j.ccr.2005.10.001. View

Garcia-Marques F, Trevisan-Herraz M, Martinez-Martinez S, Camafeita E, Jorge I, Lopez J . A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics. Mol Cell Proteomics. 2016; 15(5):1740-60. PMC: 4858952. DOI: 10.1074/mcp.M115.055905. View

10.

Wei J, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R . Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023; 210(1):46-53. PMC: 11060750. DOI: 10.1097/JU.0000000000003491. View

11.

Lin Y, Li C, Chen H, Yen C, Lin L, Huang C . The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol. 2012; 48(7):629-35. DOI: 10.1016/j.oraloncology.2012.01.014. View

12.

Chandran U, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W . Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007; 7:64. PMC: 1865555. DOI: 10.1186/1471-2407-7-64. View

13.

Huang M, Narita S, Inoue T, Koizumi A, Saito M, Tsuruta H . Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production. Oncotarget. 2018; 8(67):111780-111794. PMC: 5762359. DOI: 10.18632/oncotarget.22908. View

14.

Xun G, Hu W, Li B . PTEN loss promotes oncogenic function of STMN1 via PI3K/AKT pathway in lung cancer. Sci Rep. 2021; 11(1):14318. PMC: 8275769. DOI: 10.1038/s41598-021-93815-3. View

15.

Li C, Lu K, Yang C, Du W, Liang Z . EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1. J Clin Lab Anal. 2023; 37(2):e24825. PMC: 9937894. DOI: 10.1002/jcla.24825. View

16.

Lin Y, Huang S, Wu J, Chu T, Huang S, Lee C . Novel HDGF/HIF-1α/VEGF axis in oral cancer impacts disease prognosis. BMC Cancer. 2019; 19(1):1083. PMC: 6849302. DOI: 10.1186/s12885-019-6229-5. View

17.

Cho S, Moon H, Loh T, Jang H, Liu Y, Zhou J . Splicing inhibition of U2AF65 leads to alternative exon skipping. Proc Natl Acad Sci U S A. 2015; 112(32):9926-31. PMC: 4538632. DOI: 10.1073/pnas.1500639112. View

18.

Mehra R, Kumar-Sinha C, Shankar S, Lonigro R, Jing X, Philips N . Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011; 17(12):3924-32. PMC: 3117947. DOI: 10.1158/1078-0432.CCR-10-3120. View

19.

Gatto L, Lilley K . MSnbase-an R/Bioconductor package for isobaric tagged mass spectrometry data visualization, processing and quantitation. Bioinformatics. 2011; 28(2):288-9. DOI: 10.1093/bioinformatics/btr645. View

20.

Yenerall P, Das A, Wang S, Kollipara R, Li L, Villalobos P . RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell Chem Biol. 2019; 27(1):105-121.e14. PMC: 8048778. DOI: 10.1016/j.chembiol.2019.12.005. View